Answers are grounded in this paper and cite their sources.
Percentages are based on the number of patients randomized with non-missing data. a First complete remission duration of 90 days to 12 months. b Per World Health Organization 2008 criteria. c ECOG PS missing in three patients. d Per National Comprehensive Cancer Network Treatment Guidelines, AML, v2.2010; cytogenetic risk not available in 135 patients. e Does not include transplant conditioning cycles (ten patients [five in each treatment arm] received one prior transplant conditioning cycle). AML: acute myeloid leukemia; ECOG PS: Eastern Cooperative Oncology Group performance status; ITT: intent-to-treat; pla/cyt: placebo plus cytarabine; Ref/eRel: refractory and early relapsed disease; vos/cyt: vosaroxin plus cytarabine.
No takes yet. Share an insight, caveat, or question.
Ravandi et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: